Market Newsdesk

T-Mobile US, Inc. to Present at the Oppenheimer 5G Summit

BELLEVUE, Wash.–(BUSINESS WIRE)–
Neville Ray, president of technology of T-Mobile US, Inc. (NASDAQ: TMUS), will present and provide a business update on Tuesday, December 15, 2020 at 11:30 a.m. Eastern Time (ET) at the Oppenheimer 5G Summit.

A live webcast of the virtual event will be available on the Company’s Investor Relations website at http://investor.t-mobile.com. An on-demand replay will be available shortly after the conclusion of the presentation.

To automatically receive T-Mobile financial news by e-mail, please visit the T-Mobile Investor Relations website, http://investor.t-mobile.com, and subscribe to E-mail Alerts.

About T-Mobile US, Inc.

T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: http://www.t-mobile.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005261/en/

Investor Contact:

[email protected]

KEYWORDS: Washington United States North America

INDUSTRY KEYWORDS: Networks Internet Mobile/Wireless Technology Telecommunications

MEDIA:

Logo

Thunderbird Entertainment Group Announces AGM 2020 Results

VANCOUVER, British Columbia–(BUSINESS WIRE)–
Thunderbird Entertainment Group Inc. (TSXV: TBRD, OTCQX: THBRF) (Thunderbird or the Company), today announced that shareholders overwhelmingly approved all matters considered at the Company’s Annual General Meeting (“AGM”) held December 8, 2020. Details of the voting results are provided in this release.

Voting Results

Full details of the following matters that were voted on at the AGM of Company shareholders, held on December 8 2020, are set out in the Company’s management information circular dated October 31, 2020 (the “Information Circular”), which is available on SEDAR at www.sedar.com.

1. Election of Directors

The following persons were elected to serve as directors of the Company, with the outcome of votes being as follows:

Nominee	% of Votes For	% of Votes Withheld
Timothy Gamble	98.1%	1.9%
Frank Giustra	99.9%	0.1%
Frank Holmes	99.9%	0.1%
Azim Jamal	99.9%	0.1%
Jennifer Twiner McCarron	99.8%	0.2%
Brian Paes-Braga	98.1%	1.9%
Paul Sparkes	99.9%	0.1%
Marni Wieshofer	99.9%	0.1%

2. Appointment of Auditor

PricewaterhouseCoopers LLP was re-appointed as the auditor of the Company for the ensuing year and the Directors were authorized to fix their remuneration.

% of Votes For	% of Votes Withheld
100%	0%

3. Annual Re-Approval of Stock Option Plan

The Company’s incentive stock option plan was approved.

% of Votes For	% of Votes Against
99.9%	0.1%

Leadership Transition

Mark Miller, who joined the Board in 2015, has decided to step down as Director to focus on production. Mr. Miller is also stepping down as President of Thunderbird and CEO of Great Pacific Media (GPM). Mr. Miller is taking on a new role within GPM as Executive Producer, which allows him to focus on creative work. He remains a senior member of the creative team, which is responsible for numerous international hit television series including Highway Thru Hell. Mr. Miller will also work with the development team to create new hits.

“It has been an incredible adventure growing Great Pacific, and joining the Thunderbird Family. This decision allows me to put 100% of my time into creating content that will strengthen Thunderbird as a global IP leader,” said Mr. Miller.

“Mark has been an integral part of the Thunderbird story, and we support his decision to follow his passions by turning incredible stories into premium content that global audiences can enjoy,” said Jennifer Twiner McCarron, CEO, Thunderbird. “Mark is recognized throughout the industry as a talented showrunner and top producer, and we look forward to him building on GPM’s already impressive slate with more great shows.”

The Company would like to thank Mr. Miller for his many contributions as a board member, a part of the senior management team, and for his nimble leadership at the onset and throughout the global pandemic.

Ms. Jennifer Twiner McCarron has been appointed as President of Thunderbird in addition to her role as company CEO. David Way will continue as the President of GPM with the role of CEO for the Factual Division being eliminated.

Grant of Stock Options

Following the AGM, the Board of Directors authorized the grant of an aggregate of 360,000 incentive stock options in accordance with the terms of the Company’s stock option plan to employees at the management level. The options are exercisable at a price of $3.00 per share and have a seven year term, subject to vesting provisions.

For information on Thunderbird and to subscribe to the Company’s investor list for news updates, go to www.thunderbird.tv.

About Thunderbird Entertainment Group

Thunderbird Entertainment Group is a global award-winning, full-service, multiplatform production, distribution, and rights management company, headquartered in Vancouver, with additional offices in Los Angeles, Toronto, and Ottawa. Thunderbird creates award-winning scripted, unscripted, and animated programming for the world’s leading digital platforms, as well as Canadian and international broadcasters. Thunderbird’s vision is to produce high quality, socially responsible content that makes the world a better place. The Company develops, produces, and distributes animated, factual, and scripted content through its various divisions, including Thunderbird kids and family (Atomic Cartoons), Thunderbird factual (Great Pacific Media) and Thunderbird productions. Thunderbird is on Facebook, Twitter, and Instagram at @tbirdent. For more information, visit: www.thunderbird.tv.

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility of the adequacy or accuracy of this release, which has been prepared by management.

Cautionary Statement Regarding Forward-Looking Information

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the Company’s objectives, goals or future plans and the business and operations of the Company. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; those additional risks set out in the Company’s Filing Statement and other public documents filed on SEDAR at www.sedar.com; and other matters discussed in this news release. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005269/en/

Investor Relations:

Glen Akselrod, Bristol Capital

Phone: + 1 905.326.1888 ext 1

Email: [email protected]

Media Relations:

Julia Smith, Finch Media

Phone: +1604.803.0897

Email: [email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: TV and Radio Entertainment Online Film & Motion Pictures

MEDIA:

Logo

University of Maryland Global Campus and Apex Systems Team Up to Increase Upskilling and Reskilling for Apex Consultants and Employees with a Focus on Military Veterans in Cybersecurity Careers

ADELPHI, Md.–(BUSINESS WIRE)–
University of Maryland Global Campus (UMGC), the largest online public university in the country, and Apex Systems, a world-class technology services firm, announced today an alliance whose goal is to increase upskilling and reskilling Apex consultants and employees with a focus on military veterans getting jobs in the cybersecurity field.

As part of the alliance, UMGC will offer tuition discounts for the university’s courses to individuals who complete its Cyber Security Analyst Training Program. Also, Apex internal employees or consultants who pass certain IT industry certification exams can receive credit toward certificate and academic degree programs at UMGC.

“This is a win-win-win, for UMGC and Apex Systems, but most especially Apex students, who will have increased opportunities to improve their skill sets, especially our veterans who may have had some training while on active duty but lack a degree that would allow them to start a career in cybersecurity,” said Blakely Pomietto, UMGC’s Chief Academic Officer. “The combination of experience—which a veteran or those in the civilian workforce may be able to get credit for—and training obtained through the Apex program can accelerate a student’s path to a bachelor’s or master’s degree and career success.”

“This alliance strengthens Apex’s focus to help retain the best talent while upskilling them in the workforce,” said Damon Phillips, Executive Managing Director of Advanced Programs and Federal Strategic Alliances at Apex Systems. “The alliance broadens the upskilling program, Apex Talent University, which is already in place. It deepens the strength in our Workforce Mobilization solutions for our consultants and clients, while enhancing our commitment to military veterans who want to expand on what they may have learned in their military service. We provide the opportunity for them to seek a rewarding career while continuing their education at a discount through the UMGC program.”

Under the UMGC-Apex alliance, Apex students who enroll at UMGC will receive a discount on the out-of-state tuition. Graduates of the Apex cybersecurity training program or clients who complete CompTIA Network+, CompTIA Security+ or EC-Council Certified Ethical Hacker (CEH) certifications can receive academic credit at UMGC and speed up the time to earn a degree.

About University of Maryland Global Campus

University of Maryland Global Campus (formerly University of Maryland University College) is a world leader in innovative educational models, with award-winning online programs in disciplines including biotechnology, cybersecurity, data analytics, and information technology that are in high demand in today’s increasingly technical, global workplace.

With an enrollment of some 90,000 students, UMGC offers open access with a global footprint and a specific mission—to meet the learning needs of students whose responsibilities may include jobs, family, and military service. The university offers both undergraduate and graduate degree and certificate programs, including doctoral programs.

A pioneer in distance education since 1947, UMGC today is harnessing the power of learning science and technology to deliver high quality, low cost, accessible higher education.

For more information on this program and eligibility please email us at [email protected].

About Apex Systems – Apex Systems is a world class technology services business that incorporates industry insights and experience to deliver solutions that fulfill our clients’ digital visions. We provide a continuum of service from workforce mobilization and modern enterprise solutions to digital innovation to drive better results and bring more value to our clients. Apex transforms our customers with modern enterprise solutions tailored to the industries we serve. Apex has a presence in over 70 markets across US, Canada and Mexico. Apex is a segment of ASGN Incorporated. (NYSE: ASGN). To learn more, visit www.apexsystems.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005274/en/

Shelly Bandas, Communications Manager

[email protected]

KEYWORDS: United States North America Maryland

INDUSTRY KEYWORDS: Technology Professional Services Small Business Security Other Education Other Technology Training Telecommunications Software Networks Education Other Professional Services Internet Hardware Human Resources Finance Consulting

MEDIA:

Logo

NantHealth Presents Significant Treatment Insights at the 2020 San Antonio Breast Cancer Symposium in a Time of Need with the Pandemic’s Impact on Cancer Care

• NantHealth’s study data shows:
  • Adoption of trastuzumab biosimilars in treatment of HER2-positive breast cancer is significant; does not appear to have been affected by patient selection, stage of disease, or goals of care.
  • Potentially significant clinical and cost benefits of trastuzumab biosimilars use in breast cancer treatment.

EL SEGUNDO, Calif. & SAN ANTONIO, Texas–(BUSINESS WIRE)–NantHealth, Inc. (NASDAQ: NH), a provider of enterprise solutions that help businesses transform complex data into actionable insights, today presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS) new significant findings around the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer and the potential clinical and cost benefits of biosimilars. NantHealth’s presentation demonstrated that the adoption of trastuzumab biosimilars does not appear to be affected by patient selection, stage of disease, or goals of care.

The study examined data from NantHealth’s Eviti Connect, an evidence-based treatment decision platform that gives providers and payers confidence to prescribe and reimburse high-quality, high-value cancer care. The data was collected from treatment plans submitted from June 2019 through October 31, 2020, for patients with HER2-positive breast cancer. The study looked at the effect of multiple factors on adoption, including physician confidence in biosimilar efficacy and efficacy across stages, practice reimbursement, as well as payer medical policy and redirection.

The study results indicate that adoption of trastuzumab biosimilars has increased over time across all stages of breast cancer. The choice of brand over biosimilar does not appear to be based on whether a therapy is curative or palliative (biosimilar use was higher in the curative setting) and trastuzumab biosimilar use in practice increases when payer policy favors that use. Consequently, the data infers an opportunity for payers to successfully redirect providers to biosimilars that offer high-value care at lower costs, when utilizing technology, such as Eviti Connect. Additionally, the adoption of trastuzumab biosimilars is estimated to impact societal savings significantly.

“These findings are exciting as they show that the oncology community is using biosimilars to provide high-quality cancer care while lowering overall costs. This approach also highlights the opportunity to apply real-world data to understand and improve the delivery of valuable oncology care,” said William Flood, MD, Chief Medical Officer, Eviti at NantHealth.

Presentation Details

Title: “Real-world data on the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer”

Authors: William A. Flood, MD, MS; Tiffany Avery, MD; Vlad Kozlovsky; Neil Margolis, Ph.D.; Sandeep K. Reddy, MD

Poster Number: PS9-63

Date and Time: December 9, 2020 at 8 am CT

The San Antonio Breast Cancer Symposium, held virtually from December 8-11, 2020, provides information on breast cancer research, creating a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.

About NantHealth, Inc.:

NantHealth, a member of the NantWorks ecosystem of companies, provides enterprise solutions that help businesses transform complex data into actionable insights. By offering efficient ways to move, interpret, and visualize complex and highly sensitive information, NantHealth enables customers in healthcare, life sciences, logistics, telecommunications, and other industries to automate, understand, and act on data while keeping it secure and scalable. NantHealth’s product portfolio comprises the latest technology in payer/provider collaboration platforms for real-time coverage decision support (Eviti and NaviNet); molecular analysis (GPS Cancer); and data solutions that provide multi-data analysis, reporting, and professional services offerings. OpenNMS, a NantHealth subsidiary, helps businesses monitor and manage network health and performance. For more information, visit nanthealth.com, follow us on Twitter, Facebook, and LinkedIn, and subscribe to our blog.

Forward-Looking Statement

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers’ key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to integrate OpenNMS into our operations;; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005288/en/

MEDIA CONTACT

Jen Hodson

NANT

[email protected]

562-397-3639

KEYWORDS: California Texas United States North America

INDUSTRY KEYWORDS: Technology Hospitals Practice Management Other Health Managed Care Health General Health Data Management Oncology

MEDIA:

Logo

Bank of America Joins CVS Health to Fund and Deliver Free Flu Vaccine Vouchers

Distributes 20 Million Masks and Additional PPE to Communities in Need

CHARLOTTE, N.C.–(BUSINESS WIRE)–
As part of Bank of America’s $1 billion, four-year commitment to advance racial equality and economic opportunity, the company today announced that it will work with CVS Health to fund a no-cost flu voucher program for under-resourced communities across the U.S., including Black/African American, Native American and Hispanic-Latino populations that may not have access to low- or no-cost preventative flu shots. The program will initially be rolled out in seven cities, including Detroit, Dallas, Jacksonville, Oklahoma City, Phoenix, Boston and Greater Washington, D.C., through no-cost vouchers distributed by key nonprofit partners that serve households most in need.

“Underserved communities have been hit particularly hard by COVID-19, so supporting flu prevention in these communities is even more important,” said Eileen Howard Boone, senior vice president of Corporate Social Responsibility and Philanthropy, CVS Health. “Working together with other community-minded companies like Bank of America and our nonprofit partners, we are able to expand our reach to individuals who may not otherwise have access to flu vaccines.”

Bank of America is also providing a further round of personal protective equipment (PPE), including 5 million additional masks, 2.5 million pairs of gloves and a further 160,000 8-ounce bottles of hand sanitizer to communities most impacted by rising coronavirus cases. This is on top of the 15 million masks and 58,000 8-ounce bottles of hand sanitizer Bank of America has already donated this year to vulnerable and underserved communities.

“We are committed to working with the public and nonprofit sectors as one global community to address this health crisis and to provide the necessary resources to protect our most vulnerable populations,” said Andrew Plepler, head of Environmental, Social and Governance at Bank of America. “Offering access to free flu prevention complements our other health-focused efforts including supplying PPE, supporting community-based testing and care, addressing food insecurity and providing access to mental health resources.”

Bank of America’s work with CVS Health and the company’s ongoing PPE donations build on its continued health and health care-focused investments in the communities it serves. This year, the bank has invested more than $100 million in local communities to address coronavirus-related challenges.

Recent Bank of America announcements focused on racial equality, diversity and inclusion, and economic opportunity include:

• Bank of America Gives 21 Higher Education Institutions $1 Million Each as Part of Recently Announced $25 Million Jobs Initiative
• Ten Completed Equity Investments in Minority Depository Institutions and Community Development Financial Institution Banks
• $2 Billion Equality Progress Sustainability Bond
• Universal ESG Reporting; International Business Council of World Economic Forum
• Recognition as Top Global Bank on Fortune’s “Change the World” List
• $300 Million of Its $1 Billion, Four-Year Commitment to Advance Racial Equality and Economic Opportunity
• Support of Boys & Girls Clubs of America With $1 Million Grant to Support Educational Programs
• $1 Billion, Four-Year Commitment to Support Economic Opportunity Initiatives
• $250 Million in Capital and $10 Million in Philanthropic Grants to Community Development Financial Institutions (CDFIs)

Bank of America

At Bank of America, we’re guided by a common purpose to help make financial lives better, through the power of every connection. We’re delivering on this through responsible growth with a focus on our environmental, social and governance (ESG) leadership. ESG is embedded across our eight lines of business and reflects how we help fuel the global economy, build trust and credibility, and represent a company that people want to work for, invest in and do business with. It’s demonstrated in the inclusive and supportive workplace we create for our employees, the responsible products and services we offer our clients, and the impact we make around the world in helping local economies thrive. An important part of this work is forming strong partnerships with nonprofits and advocacy groups, such as community, consumer and environmental organizations, to bring together our collective networks and expertise to achieve greater impact. Learn more at about.bankofamerica.com, and connect with us on Twitter (@BofA_News).

For more Bank of America news, including dividend announcements and other important information, visit the Bank of America newsroom and register for news email alerts.

www.bankofamerica.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005357/en/

Reporters may contact:

Vanessa Cook, Bank of America

Phone: 1.980.683.2247

[email protected]

KEYWORDS: Rhode Island North Carolina United States North America

INDUSTRY KEYWORDS: Finance Banking Professional Services Hispanic Philanthropy Other Health Health Consumer Other Philanthropy

MEDIA:

Logo

RRD Announces Vaccination Distribution Toolkit to Support Marketing and Operations for Pending COVID-19 Vaccine

CHICAGO–(BUSINESS WIRE)–
R.R. Donnelley & Sons Company (RRD) (NYSE: RRD), a leading global provider of marketing and business communications, today introduces a comprehensive vaccination distribution toolkit — for healthcare providers, government agencies, retail pharmacies, and large enterprise organizations — aimed at delivering quick-turn marketing, communication, and operational support upon the release of an FDA-authorized COVID-19 vaccine.

With several COVID-19 vaccines under review for Emergency Use Authorization by the FDA, manufacturers, care providers, and associated companies will have an immediate need for vaccine distribution, related communication, and support materials.

Immediate production of a vaccine program involves many components, e.g., regulatory compliance, multiple vendor coordination, and speed-to-market challenges. RRD’s vaccination distribution toolkit is designed to provide turnkey support in three key areas:

1. Vaccine awareness – direct mail campaigns, digital communications, employee training materials, content and creative translations
2. Clinician and retailer operational needs – signage and wayfinding, prep kits, temperature labels, POP displays, branded promotions and labels
3. Post-vaccination support – care kits, proof of vaccination, second-dose reminders, tip sheets

The challenge of any large-scale, intra-pandemic vaccination effort is often compounded by the fact that many people are reluctant to get vaccinated. According to a recent survey by Sermo, more than 80% of physicians indicate that concerns regarding the safety of the COVID-19 vaccine could be the main barrier to adoption. Widespread vaccination will require extensive communications that thoughtfully incorporates messaging, imagery, reading level, and translation to resonate with a variety of populations.

“RRD’s new vaccination distribution toolkit is rooted in the company’s expertise in creating compelling communications distributed through direct mail, online channels, and physical locations,” said Ken Gammon, Vice President, RRD Healthcare Solutions.

“Once a vaccine becomes available, its distribution will require swift, efficient mobilization of awareness campaigns and associated materials. This focused coordination of proven RRD solutions will not only empower businesses with a true sense of preparedness, but provide them access to the right tools to effectively and safely seize the moment.”

About RRD

RRD is a leading global provider of multichannel business communications services and marketing solutions. With more than 35,000 employees across 29 countries, RRD offers the industry’s most comprehensive offering of solutions designed to help companies—from Main Street to Wall Street—optimize customer engagement and streamline business operations across the complete customer journey. RRD offers a comprehensive portfolio of capabilities, experience and scale that enables organizations around the world to create, manage, deliver, and optimize their marketing and business communications strategies. For more information, visit the Company’s web site at www.rrd.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005241/en/

Katie O’Rourke

Director, RRD Corporate Communications

[email protected]

312-326-7168

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Other Health General Health Internet Data Management Technology Infectious Diseases Other Communications Publishing Marketing Communications Other Technology Health Telecommunications

MEDIA:

Posted on December 9, 2020 9:03 am

Emerson to Modernize TVA Power Plant for Reliable, Clean Energy

Emerson to Modernize TVA Power Plant for Reliable, Clean Energy

Digital transformation technologies, expertise from Emerson to support TVA’s goal of ensuring long-term, responsive power delivery from its fleet

PITTSBURGH–(BUSINESS WIRE)–
The Tennessee Valley Authority (TVA) has selected Emerson (NYSE:EMR), a global software, technology and engineering leader, to modernize and optimize its Magnolia power plant that delivers reliable, cleaner electricity to customers. The Magnolia project is part of TVA’s five-year, $110 million investment to install digital technologies across its power generating fleet. Emerson’s software and technologies will support TVA’s efforts to digitally transform the Mississippi plant through advanced operations, enhanced cybersecurity and digital twin-enabled training.

TVA is the United States’ largest public power provider, supplying electricity to companies that serve 10 million people in the seven-state Tennessee Valley region. The 980-megawatt Magnolia plant, in operation since 2003, uses combined cycle technology, generating up to 50% more electricity from natural gas while producing less emissions than other sources.

Reliable, responsible operations are critical to meet the region’s growing power needs, and legacy technologies – which are more expensive and difficult to maintain – present a challenge. Emerson will replace existing systems at the combined-cycle plant with its Ovation™ automation system and software. Digital twin technologies will provide advanced training to operators, enabling them to respond quickly and safely to power generation demands. Robust cybersecurity technologies are integral to Emerson’s comprehensive solution that is designed to enhance and secure operations at the Magnolia facility.

“These upgrades are part of a larger long-term asset strategy to maintain our existing fleet in such a way that we can depend on their operation for years to come,” said Allen Clare, TVA vice president for gas & hydro operations.

Emerson and TVA are using virtual technologies in place of face-to-face interaction to keep the project moving forward during the COVID-19 pandemic.

“TVA is committed to digitally transforming its fleet so it can provide more reliable and cleaner electricity to its customers,” said Bob Yeager, president of Emerson’s power and water business. “Our technologies have allowed us to keep this critical project on schedule and prioritize the safety of communities and operations.”

The Magnolia project is expected to be completed in 2022. TVA provides power to most of Tennessee and portions of Alabama, Mississippi, Kentucky, Georgia, North Carolina and Virginia.

Emerson has been ranked the leading distributed control systems provider for the global power generation industry, according to Omdia.¹

¹Omdia, Distributed Control Systems Report, 2020. Market share based on revenue. Results are not an endorsement of Emerson. Any reliance on these results is at the third-party’s own risk.

About Emerson

Emerson (NYSE: EMR), headquartered in St. Louis, Missouri (USA), is a global technology and engineering company providing innovative solutions for customers in industrial, commercial and residential markets. Our Automation Solutions business helps process, hybrid and discrete manufacturers maximize production, protect personnel and the environment while optimizing their energy and operating costs. Our Commercial and Residential Solutions business helps ensure human comfort and health, protect food quality and safety, advance energy efficiency and create sustainable infrastructure. For more information visit Emerson.com.

This news release and a high-resolution photo are also available online. Visit: https://www.emerson.com/en-us/news/automation/20-12-tennessee-valley-authority-modernization

Follow news from Emerson’s Power & Water Solutions business on Twitter: http://twitter.com/OvationUsers

Additional resources:

• Emerson’s solutions for gas power plants
• Join the Emerson Exchange 365 Community
• Connect with Emerson via TwitterFacebookLinkedInYouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005179/en/

For Emerson

Denise Clarke

Phone: 512-587-5879

Email: [email protected]

KEYWORDS: United States North America Tennessee Missouri Pennsylvania

INDUSTRY KEYWORDS: Other Energy Utilities Oil/Gas Nuclear Coal Alternative Energy Energy Steel Packaging Engineering Chemicals/Plastics Manufacturing

MEDIA:

Logo

ACCO Brands Corporation Announces Participation in Noble Capital Markets’ Virtual Road Show Series

LAKE ZURICH, Ill.–(BUSINESS WIRE)–
ACCO Brands Corporation (NYSE: ACCO) today announced that its management will participate in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek. The virtual road show will feature a presentation from Boris Elisman, ACCO Brands Chairman and Chief Executive Officer, followed by a Q&A session proctored by Noble Senior Research Analyst Joe Gomes, featuring questions submitted by the audience.

The live broadcast of the virtual road show is scheduled for December 16, 2020, at 1 p.m. EST. Registration is free but is limited to 100 people. Register Here. The presentation also will be accessible through the Investor Relations section of www.accobrands.com or through Channelchek.com and will be archived on both websites following the event.

About ACCO Brands Corporation

ACCO Brands Corporation (NYSE: ACCO) is one of the world’s largest designers, marketers and manufacturers of branded academic, consumer and business products. Our widely recognized brands include Artline®, AT-A-GLANCE®, Barrilito®, Derwent®, Esselte®, Five Star®, Foroni®, GBC®, Hilroy®, Kensington®, Leitz®, Mead®, Quartet®, Rapid®, Rexel®, Swingline®, Tilibra®, Wilson Jones® and many others. Our products are sold in more than 100 countries around the world. More information about ACCO Brands, the Home of Great Brands Built by Great People, can be found at www.accobrands.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005176/en/

Christine Hanneman

Investor Relations

(847) 796-4320

Julie McEwan

Media Relations

(937) 974-8162

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Retail Other Manufacturing Other Retail Manufacturing

MEDIA:

Logo

Mirum Pharmaceuticals and Oberland Capital Announce Up to $210 Million Funding Arrangement

– $60 million upfront, including a $10 million equity investment, $65 million at FDA’s acceptance of NDA for maralixibat for ALGS, $35 million upon FDA approval of maralixibat in ALGS, and up to $50 million to fund in-licensing and acquisitions

– Funding agreement to support the commercialization of maralixibat for the treatment of cholestatic pruritus in patients with ALGS in the United States and for patients with PFIC2 in Europe, and for continued development of Mirum’s pipeline of treatments to address cholestatic liver diseases in children and adults

FOSTER CITY, Calif.–(BUSINESS WIRE)–
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Oberland Capital Management LLC (Oberland Capital) today announced a $200 million capped, tiered, revenue-based funding agreement based on net revenues of maralixibat, as well as a $10 million equity investment agreement. Under the agreements, Mirum will receive:

• $60 million by December 31, 2020, including a $10 million equity investment;
• $65 million upon announcement of the U.S. Food and Drug Administration’s (FDA) acceptance of Mirum’s New Drug Application (NDA) for maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS);
• $35 million upon announcement of FDA approval of maralixibat for cholestatic pruritus in patients with ALGS; and
• $50 million, at the option of Oberland Capital, which may be funded to support in-licensing or acquisition of assets to further build upon Mirum’s development and commercialization pipeline in the pursuit of treatments for rare liver diseases.

Mirum is submitting a rolling NDA to the FDA for maralixibat for the treatment of cholestatic pruritus in patients with ALGS, which it expects to complete in the first quarter of 2021, with launch planned in the second half of 2021. Mirum has also submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for maralixibat for the treatment of patients with progressive familial intrahepatic cholestasis type 2 (PFIC2), or bile salt export pump (BSEP) deficiency. The MAA was recently validated by the EMA and Mirum is preparing for launch in the European Union in the first quarter of 2022.

“The funding from Oberland Capital will enable us to invest in the launch and commercialization of maralixibat in the United States and Europe,” said Ian Clements, PhD, chief financial officer at Mirum. “The agreement with Oberland Capital provides us the support and flexibility to advance our pipeline focused on rare liver diseases for children and adults, an area where there is tremendous need.”

“We are pleased to support Mirum as they seek to commercialize new medicines for diseases with high unmet need,” said Andrew Rubinstein, managing partner of Oberland Capital. “The Mirum team has a clear vision and the potential to bring a transformative medication to the ALGS and PFIC2 patient communities and to establish itself as the leader in the treatment of cholestatic liver diseases.”

Citi acted as Financial Advisor to Mirum on the transaction.

About Maralixibat

Maralixibat is a novel, minimally absorbed, orally administered investigational drug being evaluated in several cholestatic liver diseases. Maralixibat inhibits the apical sodium-dependent bile acid transporter (ASBT), resulting in more bile acids being excreted in the feces, leading to lower levels of bile acids systemically, thereby potentially reducing bile acid mediated liver damage and related effects and complications. More than 1,600 individuals have received maralixibat, including more than 120 children who have received maralixibat as an investigational treatment for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). In the ICONIC Phase 2b ALGS clinical trial, patients taking maralixibat had significant reductions in bile acids and pruritus compared to placebo, as well as reduction in xanthomas and accelerated growth long-term. In a Phase 2 PFIC study, a genetically defined subset of BSEP deficient (PFIC2), patients responded to maralixibat. The U.S. Food and Drug Administration (FDA) has granted maralixibat Breakthrough Therapy designation for treatment of pruritus associated with ALGS in patients one year of age and older and for PFIC2. Maralixibat was generally well-tolerated throughout the studies. The most frequent treatment-related adverse events were diarrhea and abdominal pain. Until maralixibat is approved by regulatory authorities and available for prescribing, the medication is available to patients with ALGS through Mirum’s expanded access program. For more information, please visit ALGSEAP.com. For more information about the Phase 3 study for maralixibat in pediatric patients with PFIC, visit PFICtrial.com.

About Mirum

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. Mirum has initiated a rolling NDA submission for maralixibat in the treatment of cholestatic pruritus in patients with ALGS and expects to complete the submission in the first quarter of 2021. Additionally, Mirum’s marketing authorization application for the treatment of pediatric patients with PFIC2 has been accepted for review (validated) by the European Medicines Agency.

Mirum is also developing volixibat, also an oral ASBT-inhibitor, in primary sclerosing cholangitis and intrahepatic cholestasis of pregnancy. For more information, visit MirumPharma.com.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.

About Oberland Capital

Oberland Capital, a private investment firm with over $2.25 billion in capital commitments since inception, is focused exclusively on investing in the global healthcare industry and specializes in flexible investment structures customized to meet the specific capital requirements and strategic objectives of transaction partners. Oberland Capital’s broad suite of financing solutions includes monetization of royalty streams, acquisition of future product revenues, creation of project-based financing structures, and investments in traditional debt and equity. With a combination of deep industry knowledge and extensive structured finance experience, the Oberland Capital team has a history of creating value for its transaction partners. The firm was founded in 2013 by Jean-Pierre Naegeli and Andrew Rubinstein.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the regulatory approval path for maralixibat in the United States and the European Union, and Mirum’s ability to meet funding conditions under its financing arrangements and access to capital thereunder and consummate acquisitions of assets or in-licenses. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans,” “will,” “may,” “expects,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general, the impact of the COVID-19 pandemic, and the other risks described in Mirum’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005350/en/

Mirum Contacts:

Investors

Ian Clements, Ph.D.

[email protected]

Media

Erin Murphy

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Finance Health Professional Services Pharmaceutical

MEDIA:

Logo

Alcoa Earns New Certifications From the Aluminium Stewardship Initiative (ASI) at Three Additional Locations in Europe

PITTSBURGH–(BUSINESS WIRE)–
Alcoa Corporation today announced that three more of its operating locations have earned certifications from the Aluminium Stewardship Initiative (ASI), the industry’s most comprehensive system for third-party validation of sustainable manufacturing processes.

The latest facilities to earn the Performance Standard certification include the Fjarðaál smelter in Iceland, the Lista smelter in Norway, and the San Ciprián refinery in Spain.

The Company now has earned Performance Standard certifications for 13 sites, including three bauxite mines, five alumina refineries, and five aluminum smelters and casthouses.

Also, ASI recently added additional Alcoa sites that are covered by the organization’s Chain of Custody (CoC) standard, which enables the Company to market products with ASI’s certification. The CoC scope now includes all of the Company’s bauxite mines in Western Australia and Brazil, all of the alumina refineries in Western Australia and the Alumar refinery in Brazil, and the aluminum smelters and casthouses at Mosjøen (Iceland), Lista (Norway), Baie-Comeau (Canada), and Fjarðaál (Iceland).

The Chain of Custody (CoC) certification and its performance standards provide independent, third-party validation and traceability of responsible production, sourcing and stewardship of aluminum.

“Alcoa has a strategic priority to advance sustainably, which includes financial, environmental and social outcomes, and our progress toward validating responsible production is a reflection of our commitment,” said Rosa García Pineiro, Vice President of Sustainability for Alcoa. “We congratulate our employees at these European locations for their work in earning this certification and operating with excellence.”

Fiona Solomon, Chief Executive Officer at ASI said: “We congratulate Alcoa on these three ASI Performance Standard Certifications in Europe. The new certifications, combined with Performance Standard and Chain of Custody Standard Certifications already achieved at other Alcoa sites are not only a further validation of company-wide efforts to implement responsible practices along the value chain, but also demonstrate the company’s continued strong support of ASI’s mission.”

Learn more about Alcoa’s sustainability approach at www.alcoa.com/sustainability and its portfolio of sustainable products at www.alcoa.com/sustana.

About Alcoa

Alcoa (NYSE: AA) is a global industry leader in bauxite, alumina, and aluminum products, and is built on a foundation of strong values and operating excellence dating back more than 130 years to the world-changing discovery that made aluminum an affordable and vital part of modern life. Since developing the aluminum industry, and throughout our history, our talented Alcoans have followed on with breakthrough innovations and best practices that have led to efficiency, safety, sustainability, and stronger communities wherever we operate. Visit us online on www.alcoa.com, follow @Alcoa on Twitter, and on Facebook at www.facebook.com/Alcoa.

Dissemination of Company Information

Alcoa Corporation intends to make future announcements regarding company developments and financial performance through its website, www.alcoa.com, as well as through press releases, filings with the Securities and Exchange Commission, conference calls and webcasts.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005109/en/

Investor Contact

James Dwyer

412-992-5450

[email protected]

Media Contact

Jim Beck

412-315-2909

[email protected]

KEYWORDS: United States Iceland North America Spain Europe Norway Pennsylvania New York

INDUSTRY KEYWORDS: Other Manufacturing Other Consumer Steel Engineering Philanthropy Manufacturing Mining/Minerals Consumer Other Philanthropy Natural Resources

MEDIA:

Logo